HLS Therapeutics Inc (HLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HLS Therapeutics Inc (HLS) has a cash flow conversion efficiency ratio of 0.105x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$6.44 Million ≈ $4.66 Million USD) by net assets (CA$61.56 Million ≈ $44.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HLS Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
HLS Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how HLS Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HLS cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
HLS Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HLS Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asefa Public Company Limited
BK:ASEFA
|
0.121x |
|
Midnight Sun Mining Corp
V:MMA
|
-0.178x |
|
Yuen Chang Stainless Steel Co Ltd
TW:2069
|
0.062x |
|
Kimlun Corporation Bhd
KLSE:5171
|
-0.030x |
|
Semen Baturaja Persero Tbk
JK:SMBR
|
0.008x |
|
Oncoclinicas do Brasil
SA:ONCO3
|
0.127x |
|
Ubiquoss Inc
KQ:264450
|
-0.022x |
|
IT City Public Company Limited
BK:IT
|
0.085x |
Annual Cash Flow Conversion Efficiency for HLS Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of HLS Therapeutics Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see HLS Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$61.56 Million ≈ $44.53 Million |
CA$16.02 Million ≈ $11.59 Million |
0.260x | +131.95% |
| 2024-12-31 | CA$71.34 Million ≈ $51.61 Million |
CA$8.00 Million ≈ $5.79 Million |
0.112x | -30.59% |
| 2023-12-31 | CA$97.70 Million ≈ $70.67 Million |
CA$15.79 Million ≈ $11.42 Million |
0.162x | +19.54% |
| 2022-12-31 | CA$125.32 Million ≈ $90.65 Million |
CA$16.94 Million ≈ $12.26 Million |
0.135x | +32.27% |
| 2021-12-31 | CA$160.74 Million ≈ $116.27 Million |
CA$16.43 Million ≈ $11.88 Million |
0.102x | +85.14% |
| 2020-12-31 | CA$169.25 Million ≈ $122.43 Million |
CA$9.34 Million ≈ $6.76 Million |
0.055x | -62.75% |
| 2019-12-31 | CA$178.20 Million ≈ $128.91 Million |
CA$26.41 Million ≈ $19.10 Million |
0.148x | -28.28% |
| 2018-12-31 | CA$158.49 Million ≈ $114.65 Million |
CA$32.75 Million ≈ $23.69 Million |
0.207x | +37.20% |
| 2017-12-31 | CA$180.38 Million ≈ $130.49 Million |
CA$27.17 Million ≈ $19.65 Million |
0.151x | +3562.31% |
| 2016-12-31 | CA$24.97 Million ≈ $18.06 Million |
CA$-108.62K ≈ $-78.58K |
-0.004x | +96.16% |
| 2015-12-31 | CA$26.03 Million ≈ $18.83 Million |
CA$-2.94 Million ≈ $-2.13 Million |
-0.113x | -129.05% |
| 2014-12-31 | CA$46.75 Million ≈ $33.82 Million |
CA$18.21 Million ≈ $13.17 Million |
0.389x | -12.46% |
| 2013-12-31 | CA$40.53 Million ≈ $29.32 Million |
CA$18.03 Million ≈ $13.04 Million |
0.445x | -14.10% |
| 2012-12-31 | CA$40.99 Million ≈ $29.65 Million |
CA$21.23 Million ≈ $15.36 Million |
0.518x | -5.88% |
| 2011-12-31 | CA$32.56 Million ≈ $23.55 Million |
CA$17.92 Million ≈ $12.96 Million |
0.550x | -27.03% |
| 2010-12-31 | CA$33.23 Million ≈ $24.04 Million |
CA$25.06 Million ≈ $18.13 Million |
0.754x | +408.59% |
| 2009-12-31 | CA$35.90 Million ≈ $25.97 Million |
CA$5.32 Million ≈ $3.85 Million |
0.148x | -24.36% |
| 2008-12-31 | CA$28.33 Million ≈ $20.50 Million |
CA$5.55 Million ≈ $4.02 Million |
0.196x | -55.32% |
| 2007-12-31 | CA$50.09 Million ≈ $36.24 Million |
CA$21.98 Million ≈ $15.90 Million |
0.439x | +1816.11% |
| 2006-12-31 | CA$30.72 Million ≈ $22.23 Million |
CA$703.50K ≈ $508.90K |
0.023x | -94.50% |
| 2005-12-31 | CA$30.02 Million ≈ $21.72 Million |
CA$12.50 Million ≈ $9.04 Million |
0.416x | +208.31% |
| 2004-12-31 | CA$18.42 Million ≈ $13.33 Million |
CA$2.49 Million ≈ $1.80 Million |
0.135x | -26.74% |
| 2003-12-31 | CA$26.67 Million ≈ $19.30 Million |
CA$4.92 Million ≈ $3.56 Million |
0.184x | -35.68% |
| 2002-12-31 | CA$24.47 Million ≈ $17.70 Million |
CA$7.01 Million ≈ $5.07 Million |
0.287x | +135.36% |
| 2001-12-31 | CA$24.45 Million ≈ $17.69 Million |
CA$2.98 Million ≈ $2.15 Million |
0.122x | -76.93% |
| 2000-12-31 | CA$12.48 Million ≈ $9.03 Million |
CA$6.59 Million ≈ $4.77 Million |
0.528x | +64.79% |
| 1999-12-31 | CA$14.22 Million ≈ $10.29 Million |
CA$4.56 Million ≈ $3.30 Million |
0.320x | +5033.98% |
| 1998-12-31 | CA$10.01 Million ≈ $7.24 Million |
CA$-64.99K ≈ $-47.01K |
-0.006x | -101.99% |
| 1997-12-31 | CA$16.91 Million ≈ $12.23 Million |
CA$5.52 Million ≈ $3.99 Million |
0.326x | -70.75% |
| 1996-12-31 | CA$8.31 Million ≈ $6.01 Million |
CA$9.27 Million ≈ $6.71 Million |
1.116x | -- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more